Rabbit antibodies for hormone receptors and her2 evaluation in breast cancer

Revista da Associacao Medica Brasileira

Volumn 55, Issue 2, 2009, Pages 163-168

  Rocha, Rafael Malagoli ^a   Nunes, Cristiana Buzelin ^a   Sanches, Fernanda Squarcio Fernandes ^a   Rocha, Gislene Fátima Silva ^a   de Oliveira, Flávio Nepomuceno ^a   Reis Filho, Jorge Sérgio ^b   Lambros, Maryou B ^b   Gobb, Helenice ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Breakthrough Breast Cancer Research Center   (United Kingdom)

Author keywords

Breast neoplasms; HER2; Hormone receptors; Immunohistochemistry; Monoclonal antibodies

Indexed keywords

EID: 67650323719     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302009000200020     Document Type: Article

References (25)

1. Oliveira VM, Aldrighi JM, Rinaldi JF. Quimioprevencão do câncer de mama. Rev Assoc Med Bras. 2006;52:453-9.
2. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol.2007;18:1133-44.
3. Gobbi H, Rocha RM, Nunes, CB. Predictive factors of breast cancer evaluated by immunohistochemistry. J Bras Med Lab. 2008;44:131-40.
4. Huang Z, Zhu W, Meng Y, Xia H. Development of new rabbit monoclonal antibody to progesterone receptor (clone SP2): no heat pretreatment but effective for paraffin section immunohistochemistry. Appl Immunohistochem Mol Morphol. 2006;14:229-33.
5. Huang Z, Zhu W, Szekeres G, Xia H. Development of new rabbit monoclonal antibody to estrogen receptor: immunohistochemical assessment on formalin-fixed, paraffin-embedded tissue sections. Appl Immunohistochem Mol Morphol. 2005;13:91-5.
6. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol. 2006;25:118-45.
7. Rocha RM, Andrade VP, Nunes CB, Rocha GFS, Sanches FSF, Oliveira FN, et al. Construção de arrays de tecido com equipamento alternativo e de baixo custo para estudo imuno-histoquímico de tumores mamários. J Bras Patol Med Lab. 2006;42:477-82.
8. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966-78.
9. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-10.
10. Harvey JN, Clark GM, Osborn CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-81.
11. Hanna W, O'Malley FP, Barnes P, Berendet R, Gaboury L, Magliocco A, et al. Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer. Curr Oncol 2007;14:149-53.
12. Lambros MBK, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol. 2007;38:1105-22.
13. Cano G, Milanezi F, Leitão D, Ricardo S, Brito MJ, Schmitt FC. Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2. Diagn Cytopathol. 2003;29:207-11.
14. Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 2006;24:5626-8.
15. Rossi S, Laurino L, Furlanetto A, Chinellato S, Orvieto E, Canal F, et al. A comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Clin Pathol. 2005;124:295-302.
16. Nunes CB, Rocha RM, Reis-Filho JS, Lambros M, Rocha GF, Sanches FS, et al. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J Clin Pathol. 2008;61:934-8.
17. Nunes CB, Rocha RM, Gouvêa AP, Tafuri LSA, Marinho VFZ, Rezende MA, Gobbi H. Concordância interobservador na interpretação imunohistoquímica da superexpressão do Her2 detectada por cinco diferentes anticorpos em arrays de carcinomas mamários. J Bras Patol Med Lab. 2007;43:365-71.
18. Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol. 2006;19:481-7.
19. Bartlett JM, Going JJ, Mallon EA, Watters AD, Reeves JR, Stanton R, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol. 2001;195:422-8.
20. McCormick SR, Lillemoe TJ, Beneke J, Schauth J, Reinartz J. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol.2002;117:935-43.
21. Wang S, Hossein SM, Frenkel EP, Haley BB, Siddiqui MT, Gokaslen SJ, et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol.2002;15:137-45.
22. Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmöller P, Gutjahr T, Kaufmann M, et al. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol. 2008;61:89-94.
23. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja M, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809-20.
24. Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, et al. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol. 2001;14:1079-86.
25. Gouvêa AP, Milanezi F, Olson SJ, Leitão D, Schmitt FC, Gobbi H. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol.2006;14:103-8.